Cargando…

HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials

SIMPLE SUMMARY: Oncolytic Herpes simplex virus-1 (HSV-1) offers the dual potential of both lytic tumor-specific cell killing and inducing anti-tumor immune responses. The HSV-1 genome can be altered to enhance both components and this may be applicable for the treatment of a broad range of cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Marilin S., Lawler, Sean E., Chiocca, E. Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760226/
https://www.ncbi.nlm.nih.gov/pubmed/33255871
http://dx.doi.org/10.3390/cancers12123514